

# 3D artificial heart tissue

Commonly used acronym: Heart Patch

Created on: 02-10-2025 - Last modified on: 02-10-2025

#### **Contact person**

Jolanda van Hengel

## **Organisation**

Name of the organisation Ghent University (UGent)

**Department** Faculty of Medicine and Health Sciences

Specific Research Group or Service Medical Cell Biology research group

**Country** Belgium

Geographical Area Flemish Region

Name of the organisation Ghent University (UGent)

**Department** Research Unit Plasma Technology

**Country** Belgium

Geographical Area Flemish Region

Name of the organisation Ghent University (UGent)

**Department** Cell Physiology and electrophysiology

**Country** Belgium

Geographical Area Flemish Region

Name of the organisation Ghent University hospital (UZ Gent)

**Department** Experimental cardiac surgery-cardiocirculatory physiology

**Country** Belgium

Geographical Area Flemish Region

Name of the organisation Interuniversitair Micro-Electronica Centrum (IMEC)

**Department** Center for Microsystems Technology

**Country** Belgium

Geographical Area Flemish Region

Name of the organisation University of Hasselt (UHasselt)

**Department** Lab of Cardiovascular Physiology

**Country** Belgium

Geographical Area Flemish Region

## **SCOPE OF THE METHOD**

| The Method relates to                    | Human health                                     |
|--|--|
| The Method is situated in                | Basic Research, Translational - Applied Research |
| Type of method                           | In vitro - Ex vivo                               |
| Specify the type of cells/tissues/organs | 3D heart   |

#### **DESCRIPTION**

## **Method keywords**

heart model

3D

Human induced Pluripotent Stem Cell

multi electrode array

plasma treatment

# Scientific area keywords

cell biology

Cardiology

cardiac function

Cardiac electrophysiology

#### **Method description**

Current pre-clinical drug safety evaluation methods remain costly, inefficient, and unreliable, with 80–90% of compounds ultimately failing in human trials — often due to poor predictive models and safety concerns. Scaffold-based 3D organ models offer a more promising and physiologically relevant alternative in pre-clinical drug testing. We aim to advance this field by optimizing a 3D artificial heart tissue model seeded with key human cell types—cardiomyocytes, fibroblasts, and endothelial cells. This model of heart patch surpasses current 3D cardiac constructs by incorporating bioinspired scaffolds and electro-mechanical stimulation to enhance cell differentiation and tissue maturity. By leveraging human induced pluripotent stem cells (iPSCs), our platform offers a more predictive and human-relevant system for cardiac drug safety and efficacy assessment, helping reduce reliance on *in vivo* animal testing.

#### **Method status**

Still in development

REFERENCES, ASSOCIATED DOCUMENTS AND OTHER INFORMATION

Coordinated by









